Mechanistically, IAP antagonists can lower the cell death-inducing threshold when combining with apoptosis inducers like venetoclax, providing another reason to explore the pro-apoptotic combination by inhibiting both IAP and BCL-2 to overcome multiple resistance to targeted and CAR T-cell therapy in MCL. Here, BCL2 is linked to mantle cell lymphoma.